Linear Capital's angel-round lead portfolio company, digital microfluidics technology platform Aoxu Technology, has completed a nearly RMB 100 million Series A funding round, with existing investor Linear Capital continuing to increase its support.

Recently, Foshan Aceso Biotechnology Co., Ltd. (hereinafter referred to as "Aceso") announced the completion of a nearly RMB 100 million Series A financing round. This round was led by Luxin Venture Capital, with existing shareholders Qiming Venture Partners, Linear Capital, and Tongchuang Weiyue continuing to increase their stakes. WinX Capital served as the exclusive financial advisor for the third consecutive round.

Zheng Can, Managing Director of Linear Capital, stated: "As the lead investor in the angel round, Linear Capital firmly believes that investing is about finding the right people. We have witnessed Dr. Ma Hanbin's transformation from a researcher to a modern entrepreneur firsthand. Dr. Ma's character, scientific literacy, cutting-edge vision, and entrepreneurial spirit have left a deep impression on us. Under his leadership, the company first launched a groundbreaking single-cell proteomics solution, adding further momentum to global proteomics research. We continued to increase our stake in this round to help propel Aceso toward becoming a benchmark enterprise in advanced scientific instruments."

Following this financing round, Aceso will further accelerate commercialization in the single-cell proteomics field, offering differentiated products and services to fill gaps in laboratory sample preprocessing, functional discovery, and validation needs, striving to bring Chinese-made advanced life science instruments to the global market.

Founded in 2021, Aceso possesses a globally leading active-matrix digital microfluidic droplet manipulation platform. In just over two years, the company has secured four consecutive funding rounds, with shareholders including numerous top-tier VC firms and well-known industry investors.

The company's first commercial product, Boxmini™ SCP, is the world's first full-process microfluidic on-chip single-cell proteomics sample preprocessing tool. It efficiently enables users to achieve high-throughput, rapid, and precise micro-sample control, completing complex single-cell protein sample preprocessing in one stop. The product is compatible with both label-free and TMT labeling protocols, and has attracted significant market attention since its launch.

Regarding this financing round, Dr. Ma Hanbin, Founder and CEO of Aceso, stated:

"By introducing consumer electronics semiconductor technology into the life sciences, the Aceso team has completed the 0-to-1 foundation: particularly in single-cell proteomics sample preprocessing applications, through active-matrix digital microfluidic chip-based nanoliter sample precision manipulation and full-process integration capabilities, we have gained recognition from multiple leading PIs both domestically and abroad, generating experiment results that promote the entire field. In other areas such as single-cell multi-omics, microbiology, and synthetic biology, Aceso will also collaborate with different downstream partners to accelerate new product development and commercialization. With the support of new and existing shareholders, we will leverage our product technology advantages to rapidly expand domestic and international markets, using single-cell proteomics products as a breakthrough point, and building a semiconductor technology-based biochip ecosystem through an open digital microfluidic sharing platform, enabling life science laboratories and medical testing to rapidly enter the consumer electronics era."

Qiu Fang, Deputy General Manager of Luxin Venture Capital, the lead investor of this round, stated:

"As a state-controlled professional venture capital institution, Luxin Venture Capital has consistently prioritized supporting the application and commercialization of China's independent research platforms and instrument achievements through venture capital, placing the task of achieving high-level sci-tech self-reliance at the forefront. Aceso has mastered the core underlying technology of active-matrix digital microfluidics, with the potential to advance laboratory automation to an entirely new level, forming new research platforms. The company's single-cell proteomics product provides advanced tools for cutting-edge research such as single-cell multi-omics, attracting strong attention from downstream customers including Luxin's portfolio companies, demonstrating that high-level self-reliance in domestic scientific instruments is about to enter a new phase. Luxin Venture Capital will support Aceso in fighting the battle for localization of scientific instruments."

Chen Kan, Partner at Qiming Venture Partners, stated:

"As the lead investor in the previous round, Qiming Venture Partners has increased its investment in Aceso for two consecutive rounds. With strong R&D capabilities and excellent execution, the company has rapidly launched cutting-edge products in the single-cell field, facing a blue ocean market. We are fully confident in the company's future and will continue to support its commercialization in overseas markets, looking forward to Aceso bringing 'Intelligent Manufacturing in China' advanced scientific instruments to the world."

Xi Yanbin, Partner at Tongchuang Weiyue Beijing Healthcare Fund, stated:

"We have always believed that Aceso's digital microfluidic chip system has the potential to become a key carrier for next-generation life science microreactors, continuously providing innovative solutions for scientific research, the pharmaceutical industry, and beyond. The company's single-cell proteomics product has advanced proteomics research to a practical single-cell granularity, enabling customers to no longer be limited by tools and to validate what they know and explore the unknown from entirely new angles. We continued to increase our stake in this round, looking forward to Aceso enabling advanced technology to fully blossom at the application level."

Zou Guowen, Founding Partner of WinX Capital, stated:

"WinX Capital is honored to serve as the exclusive financial advisor for Aceso's financing for the third consecutive round, witnessing Aceso's journey from startup to rapid development and commercialization. As a leading company in the digital microfluidics industry, Aceso has been able to navigate market cycles and secure four consecutive funding rounds in less than three years, fully demonstrating the capital market's high recognition of the company. We look forward to Aceso's further expansion in downstream fields and to becoming a world-leading life science tools enterprise."

About Linear Capital

Linear Capital is an early-stage investment institution focused on the "frontier technology + industry" direction, namely frontier technologies represented by data intelligence, digital new infrastructure, next-generation robotics technology, and new technological transformations in traditional fields (such as biomedicine, materials, energy, etc.), applied across vertical industries to substantially improve industrial efficiency, empower solutions to pain points, and complete industrial upgrading—achieving excess returns through substantial increases in industrial value. The firm currently manages ten funds with total assets under management of approximately USD 2 billion.

Our investment stage focuses primarily on angel to Series A lead investments, with typical investment amounts of USD 3 to 8 million or equivalent RMB per project.

To date, we have invested in over 120 entrepreneurial teams at early stages, including Horizon Robotics, Kujiale, Sensors Data, Tezign, Rokid, Guandata, and Agile Robots. The combined valuation of Linear Capital's portfolio companies is approximately USD 20 billion.

In the near term, Linear Capital is striving to become the best "Data Intelligence Technology Fund," and in the long term, gradually build itself into the most influential "Frontier Technology Application Fund."